NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Biocept on Monday filed with US regulators to go public with an initial public offering intended to raise up to $24.25 million.

In its Form S-1 filed with the US Securities and Exchange Commission, the San Diego-based company said that it plans to list on the Nasdaq Capital Market under ticker symbol "BIOC." It added that it expects to implement a 1-for-10 reverse stock split of its outstanding common stock before the effective time of its prospectus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.